John Hollister, MD
Emergency Medicine · Starkville, MSNPI 1689617185
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $662 and has fallen 54.3% since, to $303 in 2025. Among emergency medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$437
- Amgen$396
- AstraZeneca$348
- AbbVie$328
- Pfizer$225
- Lilly USA, LLC$205
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $437 |
| Amgen | 28 | $396 |
| AstraZeneca | 9 | $348 |
| AbbVie(2 entities) | 14 | $328 |
| Pfizer | 12 | $225 |
| Lilly USA, LLC | 12 | $205 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $112 |
| Abbott | 6 | $100 |
| Mylan Specialty L.p. | 4 | $80 |
| GSK | 5 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Daiichi Sankyo Inc. | 4 | $57 |
| Averitas Pharma Inc. | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Bayer | 3 | $47 |
| Boehringer Ingelheim | 2 | $46 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Merck | 2 | $43 |
| Global Blood Therapeutics, Inc. | 2 | $37 |
| Pacira Therapeutics, Inc. | 1 | $36 |
| Boston Scientific | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,094 in reported general payments places this provider in the 95th percentile of 443 emergency medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 277 | $235,278 |
| OzempicSemaglutide | 163 | $177,065 |
| EliquisApixaban | 92 | $64,692 |
| JardianceEmpagliflozin | 70 | $62,470 |
| JanuviaSitagliptin Phosphate | 38 | $44,984 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $27,900 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $25,269 |
| MounjaroTirzepatide | 22 | $24,142 |
| LinzessLinaclotide | 29 | $20,839 |
| RybelsusSemaglutide | 14 | $19,959 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $17,902 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 51 | $16,083 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,054 |
| TradjentaLinagliptin | 54 | $14,030 |
| MyrbetriqMirabegron | 42 | $13,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $348 | $254,786313 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $437 | $199,719197 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $46 | $88,684135 claims |
| PfizerEliquis, Abrysvo | $225 | $80,775143 claims |
| MerckJanuvia, Janumet | $43 | $72,88474 claims |
| Lilly USA, LLCMounjaro, Trulicity | $205 | $36,68035 claims |
| AbbVieLinzess, Synthroid | $328 | $24,13158 claims |
| Johnson & JohnsonXarelto | $13 | $11,66032 claims |
| GSKShingrix | $72 | $6,41829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 emergency medicine providers in Mississippi.
Other emergency medicine in Starkville
- Stanley ThompsonSouthaven$466K
- Utsav NandiJackson$54K
- Richard SummersJackson$20K
- Damon DarseyJackson$11K
- Kenneth WhittingtonHazlehurst$8K
- Samuel Richardson IiiJackson$8K
- Joseph PongettiJackson$5K
- Robert WalkerHazlehurst$5K
- Salvador ArceoBrandon$5K
- Manuel OngCarthage$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.